Videos

Clinicians discuss the particular benefits of rapid-acting agents for major depressive disorder (MDD), highlighting the gap glutamate-modulating agents fill in targeted therapies.

Experts continue their discussion on the role of glutamate receptors, explaining their role in stimulating neuroplasticity and neurogenesis.

Who helped your career?

Clinicians discuss the effects of glutamate modulation on neuroplasticity, memory, and cognitive function, highlighting their role in improving overall wellness for their patients.

Experts highlight the role of NMDA and AMPA receptors in major depressive disorder (MDD) and how new therapies are targeting novel mechanisms of action.

Clinicians discuss past treatment options compared to novel glutamate-modulating agents, highlighting their rapid onset of symptom relief.

Experts discuss the significance of glutamate in major depressive disorder, highlighting its links to neuroplasticity and stress.

"Hat factories closed quiet as prayer books, and loss lingered in my father’s guts like unswept garbage after a big parade..."

Who in your life are you grateful for?

"Perhaps the world will end at the kitchen table, while we are laughing and crying, eating of the last sweet bite."

Be kind!

How do you respond to change? What does properly adjusting to change acquire?

"Of her choice virtues only gods should speak, Or English poets who grew up on Greek (I’d have them sing in chorus, cheek to cheek)."

We need psychiatrists now more than ever...

"I know I have the blood of survivors coursing through my veins; I know the lament of our loss must warm us again and again down in the belly of the whale..."

Let's try to make the world a better place.

Gepirone, the first and only oral selective 5HT1a receptor agonist for the treatment of major depressive disorder in adults, is expected to arrive in early 2024.

"His wing Scythes down another day, his motion Is that of the honed steel-edge, we hear The crashless fall of stalks of Time."

Roger S. McIntyre, MD, FRCPC, and Carmen Kosicek, MSN, PMHNP-BC, discuss the future of MDD treatment and share closing thoughts.

Carmen Kosicek, MSN, PMHNP-BC, shares tips with patients about the use of zuranolone to treat MDD.

What do autumn leaves signify?

"The sounds of the world at this late hour sadden you, but then enters the rain, hastening down, the rain that wants to touch everything and almost does."

Don't miss the the 2023 Psychiatric Times World CME conference, where our Editor in Chief will present on the 14 different types of dementia!

Don't miss updates on schizophrenia at our conference, beginning at 3:10PM EST!

Experts in psychiatry review adverse effects of zuranolone, a γ-aminobutyric acid (GABA) receptor modulator, in the treatment of MDD.

Roger S. McIntyre, MD, FRCPC, comments on the paradigm shift of the frequency of dosing in the treatment of MDD, highlighting GABAergic modulating treatments, as well as the use of therapy to improve mental health.

How frequently is joy discussed in psychiatry?

Our Editor in Chief explains why you should attend our conference!

"My hands grown tired, my head weighed down with dreams..."

Carmen Kosicek, MSN, PMHNP-BC, shares considerations on the perception of mental health treatment among diverse cultures and ages within the United States.